Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials - Cardiovascular Diabetology
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01789-5
Background Patients with type 2 diabetes are at increased risk for cardiovascular diseases. Sodium-glucose transport 2 inhibitors (SGLT2i) have been shown to enhance cardiovascular health since their debut as a...
Conclusion: Our results appear to contradict the mainstream concepts regarding the cardiovascular effects of SGLT2i since we found no significant therapeutic benefits in SGLT2i to reduce the incidence of ACS, PAOD, or IS when compared to placebo or oral hypoglycemic drugs.
Share
Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting - A disproportionality analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36912450/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: There was no increased risk of myotoxicity reporting associated with concomitant use of SGLT2i and statins or for specific drug pairs.
Share
SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis
Source : https://www.sciencedirect.com/science/article/pii/S0019483223000433?via=ihub
Available online 11 March 2023 Author links open overlay panel Mainak Banerjee a 1 , Rimesh Pal b 1 , Kirthana Nair b , Satinath Mukhopadhyay a Show more To...
Conclusions: This meta-analysis established the place of SGLT2i as a foundational therapy among patients with HF with preserved and mildly reduced EF regardless of diabetes.
Share
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
Source : https://www.sciencedirect.com/science/article/pii/S2213177922007090?via=ihub
There is limited published information on outcome adjudication in heart failure (HF).The authors sought to compare investigator reports (IRs) to a Cli...
Conclusions: Investigator adjudication is an alternative to a CEC with similar accuracy and faster event accumulation. The use of granular (SCTI) criteria did not improve trial performance. Finally, our data suggest that consideration be given to broadening the HHF definition to include “for or with” worsening disease.
Share
-
Cardiologist Connect3yrKey Points • Source: JACC Heart Failure • Conclusion: “In this study, the investigators had a similar accuracy in detecting treatment effect and HHF [first event hospitalization primarily for heart failure] events with comparable Show More
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis
Source : https://www.sciencedirect.com/science/article/pii/S2213177923000732?via=ihub
Available online 20 February 2023 Author links open overlay panel a b c , , d e , , , , , , , k l , m n Show...
Conclusions: Patients with a recent HF hospitalization have a high risk of events. Empagliflozin reduced HF events regardless of HF hospitalization recency.
Share